Secondary Prophylaxis with Warfarin for Venous Thromboembolism

Büller, Harry R.; Prins, Martin H.
August 2003
New England Journal of Medicine;8/14/2003, Vol. 349 Issue 7, p702
Academic Journal
Editorial. Offers an editorial on the two phases in the treatment of patients with symptomatic venous thromboembolism. Therapy that consists of either subcutanous low-molecular-weight heparin or intravenous unfractionated heparin; Phase involving oral vitamin K antagonists such as warfarin; Evidence that an initial course of the direct-acting antiocoagulant heparin is warranted; Reference to a 1960 study by Barritt and Jordan; Evidence for secondary prophylaxis with vitamin K antagonists; Debate about the intensity of warfarin therapy for venous thromboembolism.


Related Articles

  • Traditional anticoagulant therapy: Why abandon half a century of success? Bussey, Henry // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS3 

    The benefits of low-molecular-weight heparins (LMWHs) over heparin and warfarin in treating and preventing thromboembolic disorders are discussed, Numerous advantages are associated with using heparin for treating and preventing thromboembolic disorders. Heparin's short half-life allows for...

  • Treatment of venous thromboembolism: duration and new options. Huisman, Menno V. // Hematology Journal;2004 Supplement 3, Vol. 5, pS24 

    Studies the treatment of venous thromboembolism. Initial treatment of choice; Evidence for the need of heparin; Optimal duration of anticoagulant therapy; Management of patients with an increased risk of recurrence.

  • Anticoagulation for venous thromboembolism. Eikelboom, John W.; Ginsberg, Jeffrey S.; Hirsh, Jack // BMJ: British Medical Journal (International Edition);3/31/2007, Vol. 334 Issue 7295, p645 

    The article presents an editorial about the use of anticoagulant therapy to treat venous thromboembolism. A randomized controlled trial in the current issue by Campbell and colleagues examined the optimal duration of oral anticoagulant therapy. The drugs warfarin and heparin were investigated in...

  • New Anticoagulants: Focus on Venous Thromboembolism. G�mez-Outes, Antonio; Lecumberri, Ram�n; Pozo, Carmen; Rocha, Eduardo // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p309 

    Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) and/or arterial thromboembolism. The therapeutic arsenal of anticoagulants available to clinicians is mainly composed by unfractionated heparin (UFH),...

  • Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Saraf, Karan; Morris, Paul; Garg, Pankaj; Sheridan, Paul; Storey, Robert // Postgraduate Medical Journal;Sep2014, Vol. 90 Issue 1067, p520 

    Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic or haemorrhagic complications. It also requires...

  • New Oral Anticoagulants: Targeted Inhibition of Factor Xa and Thrombin. Ciaccia, Antonio; Thai, John; Turpie, Alexander G. // Advances in Orthopaedics;Jun2010, Vol. 2 Issue 2, p52 

    Anticoagulants are recommended for the prevention and treatment of a wide spectrum of thromboembolic disorders. Recent developments in antithrombotic therapy have the potential to significantly impact the management of patients. Several direct thrombin and Factor Xa inhibitors are under...

  • Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate. Kendoff, D.; Perka, C.; Fritsche, H. M.; Gehrke, T.; Hube, R. // Open Orthopaedics Journal;2011, Vol. 5, p395 

    The risk of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement surgery is high. As a result, thromboprophylaxis is highly recommended. While current thromboprophylactic agents, such as low molecular weight heparins (LMWH) and vitamin K antagonists, are safe and...

  • Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. Castellucci, Lana A.; Cameron, Chris; LeGal, Grégoire; Rodger, Marc A.; Coyle, Doug; Wells, Philip S.; Clifford, Tammy; Gandara, Esteban; Wells, George; Carrier, Marc // JAMA: Journal of the American Medical Association;9/17/2014, Vol. 312 Issue 11, p1122 

    IMPORTANCE Many anticoagulant strategies are available for the treatment of acute venous thromboembolism, yet little guidance exists regarding which drug is most effective and safe. OBJECTIVE To summarize and compare the efficacy and safety outcomes associated with 8 anticoagulation options...

  • Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? Mahé, Isabelle; Sterpu, Raluca; Bertoletti, Laurent; López-Jiménez, Luciano; Mellado Joan, Meritxell; Trujillo-Santos, Javier; Ballaz, Aitor; Hernández Blasco, Luis Manuel; Marchena, Pablo Javier; Monreal, Manuel; null, null // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy with low-molecular weight heparin (LMWH) for those with cancer. We used data from RIETE (international registry of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics